Minimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. Two MIGS devices have already been approved for the U.S. market and more are in development. So are a variety of other novel devices that have the potential to transform the treatment of glaucoma.
Seven companies presented their latest devices in development or marketing during a “New Horizons in Glaucoma Devices” session as part of the New Horizons Forum at the 2017 Glaucoma 360 meeting. Malik Y. Kahook, MD, Slater Family Endowed Chair of Ophthalmology, University of Colorado, Denver, and Thomas W. Samuelson, MD, founding partner, Minnesota Eye Consultants, Minneapolis, were the sessions moderators.
